Planning for this week’s three-day adcom on US accelerated approvals for anti-PD-(L)1 drugs? Here’s the background info you need.
Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
Aveo gets Fotivda over the line in the US, but the market celebration looks misplaced.
Tecentriq follows Opdivo, Imfinzi and Keytruda in having a US approved use knocked out.